contact us

When Diagnosing Breast Cancer,
Every Moment Counts

Improved breast cancer diagnosis, better clinical outcomes
Connect with us today

Introducing the APIS Breast Cancer Subtyping Kit

For patients facing a breast cancer diagnosis, every day of waiting can feel like an eternity. Our advanced mRNA-based Breast Subtyping Kit reduces the need for time-consuming follow-up tests, by providing:

Rapid

Reliable results

Precise

Diagnostic data

Specialised

Opportunities for faster treatment decision

When Diagnosing Breast Cancer, Every Moment Counts

Improved breast cancer diagnosis, better clinical outcomes
Connect with us today

Introducing the APIS Breast Cancer Subtyping Kit

For patients facing a breast cancer diagnosis, every day of waiting can feel like an eternity. Our advanced mRNA-based Breast Subtyping Kit reduces the need for time-consuming follow-up tests, by providing:

Rapid

Reliable results

Precise

Diagnostic data

Specialised

Opportunities for faster treatment decision

A seamless, fast, and reliable breast cancer subtyping solution

How it works

The APIS mRNA Breast Subtyping Kit eliminates the need for additional, time-consuming tests, such as reflex HER2 testing, by providing a single, high-resolution method to deliver results within hours.
Read more

Providing hope for patients and their families

Precious time saved, faster treatment decisions
Obtain conclusive breast cancer subtyping results
The APIS Kit drastically reduces wait times, allowing patients to begin life-saving treatments much sooner.

Reduce valuable time waiting for results

Improve overall diagnostic accuracy

Diagnose complex cases easily

Moving beyond traditional Ki67 testing

A new standard of care in breast cancer diagnosis

By offering a novel proliferation signature, the APIS Kit ensures clinicians have precise data to guide personalised treatment plans. Our automated analysis ensures pathologists attain fast, accurate results every time, helping them provide you with the best possible care.
Connect with us today

Get the care you need to make a full recovery

Discover how the APIS Breast Cancer Subtyping Kit can give your healthcare provider a faster and more accurate diagnosis before the treatment phase.

Connect with us today to learn more about how we can help you.

Connect with us

UK office

South Africa office
  • Ground Floor, Twickenham Building,
    The Campus, Cnr Main & Sloane Street Bryanston, Johannesburg
  • +27 10 142 7093

Services

Medical technologies

Website's carbon footprint
We are committed to responsible business practices, championing SDGs in every facet of our work to achieve net-zero targets.
© 2024 Link Medical Solutions Ltd. All rights reserved. | Designed & development by The Ethical Agency

Connect with us

UK office

South Africa office
  • Ground Floor, Twickenham Building,
    The Campus, Cnr Main & Sloane Street Bryanston, Johannesburg
  • +27 10 142 7093

Services

Medical technologies

Website's carbon footprint

We are committed to responsible business practices, championing SDGs in every facet of our work to achieve net-zero targets.
© 2024 Link Medical Solutions Ltd. All rights reserved. | Designed & development by The Ethical Agency

A seamless, fast, and reliable breast cancer subtyping solution

How it works

The APIS mRNA Breast Subtyping Kit eliminates the need for additional, time-consuming tests, such as reflex HER2 testing, by providing a single, high-resolution method to deliver results within hours.
Sample preparation

COLLECT breast tissue samples for testing.

Recommended RNA extraction & normalisation

EXTRACT RNA from the samples, adjusting concentrations to ensure all tests are accurate.

APIS Breast Cancer Subtyping Kit setup

PREPARE APIS kit, including all the necessary tools and materials for identifying the category of breast cancer present.

RT-qPCR reaction

AMPLIFY extracted RNA to measure specific gene expressions and understand the underlying cancer.

Analysis and results reporting

ANALYSE data from the RT-qPCR reaction and report on breast cancer subtype identified, aiding in better, more effective treatment decisions.